| Use of duloxetine in pregnancy and lactation. | |
| | |
MedLine Citation:
|
PMID: 19809008 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To report a case of a woman who used duloxetine during pregnancy and breast-feeding. CASE SUMMARY: A 29-year-old woman was treated with duloxetine for depression during the second half of an uncomplicated gestation. She gave birth at term to a healthy female infant. A cord blood sample was obtained at birth. The mother continued the antidepressant while exclusively breast-feeding her infant. One month later, we collected blood and milk samples from the mother and a single blood sample from the infant. All samples were analyzed for the presence and concentrations of duloxetine. DISCUSSION: Duloxetine crosses the placenta at term and is excreted into breast milk. No evidence of developmental or other type of toxicity was observed in the infant at birth or during the first 32 days after birth. The published literature detailing human pregnancy experience with this antidepressant is limited to 11 cases in which women became pregnant while taking duloxetine. In 10 cases, the drug was discontinued when pregnancy was diagnosed and no outcome data were reported. In the eleventh case, an infant exposed to duloxetine 90 mg/day developed neonatal behavioral syndrome. One study examined the excretion of duloxetine into breast milk, but the mothers discontinued nursing for the study. In the present case, no adverse effects from exposure to the drug in milk were noted in the exclusively breast-fed infant. The possibility of functional/neurobehavioral deficits appearing later in life cannot be excluded because long-term follow-up has not been conducted in infants exposed to duloxetine in utero or during nursing. CONCLUSIONS: No developmental toxicity or other signs of toxicity were observed in an infant exposed to duloxetine during the second half of gestation and during breast-feeding in the first 32 days after birth. However, the possibility of functional/neurobehavioral deficits appearing later in life cannot be excluded. |
| | |
Authors:
|
Gerald G Briggs; Peter J Ambrose; Kenneth F Ilett; L Peter Hackett; Michael P Nageotte; Guadalupe Padilla |
Related Documents
:
|
17259038 - The use of breast-feeding for pain relief during neonatal immunization injections. 7430508 - Milk intakes and feeding patterns of breast-fed infants. 8312958 - Maternal factors relating to breast-feeding duration in areas around guadalajara, mexico. 106948 - Breast-feeding protects against infection in indian infants. 15507968 - Umbilical cord plasma interleukin-6 concentrations in preterm infants and risk of neona... 15829138 - Geographical characterization of the triatomine infestations in north-central guatemala. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-10-06 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 43 ISSN: 1542-6270 ISO Abbreviation: Ann Pharmacother Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2009-10-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1898-902 Citation Subset: IM |
Affiliation:
|
MemorialCare Center for Women, Miller Children's Hospital, Long Beach Memorial Medical Center, 2801 Atlantic Ave., Long Beach, CA 90806, USA. jbriggs@memorialcare.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bendamustine-associated hemolytic anemia.
Next Document: Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam usin...